SignalGene and the CHUQ Announce an Important Breakthrough in the Area of Breast Cancer by Holding a Conference Call.

Business Editors & Health/Medical Writers

BIOWIRE2K

MONTREAL--(BW HealthWire)--Aug. 7, 2001

Following the announcement of an important breakthrough in the area of breast cancer, SignalGene (TSE:SGI.)and the CHUQ are pleased to hold a conference call next August 9 at 4:00 p.m., Eastern daylight saving time, in order to discuss this discovery further.

The conference call will follow the press conference that will take place on August 9 at 2:00 p.m. in the CHUQ premises as well as the news release that will be distributed around 3:00 p.m.

Should you wish to take part in the conference call, we invite you to dial the toll-free number 1 [phone]. Please provide the operator with the following password in order to join in the conference call: CHUQ / SGI.

To access the replay of the conference call, please dial 1 [phone] followed by the access code 870321 plus #. The replay will be available approximately one hour following the conference call completion through to August 16, 2001.

SignalGene is an integrated genomics drug discovery company committed to creating value for its shareholders through the discovery, development and commercialization of high-quality drug candidates for human therapy. The Company's technologies combine genomics-based target discovery and computer-assisted drug design to generate novel small molecule drug candidates. Internal programs are focused in the area of steroid hormone signaling with proprietary targets and compounds in the areas of breast cancer, osteoporosis and obesity. The shares of the Company are listed on the Toronto Stock Exchange under the symbol SGI.

SignalGene Inc.

8475 Christophe-Colomb Avenue, Suite 1000

Montreal, QC, H2M 2N9, CANADA

Phone: [phone] or 1 [phone] - Facsimile: [phone]

Website: http://www.signalgene.com